Tokyo Women's Medical University
12
1
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Pemafibrate for Symptomatic ICAS RCT
Role: lead
The Medical Management in Patients Exposed to Weapons of Mass Destruction
Role: collaborator
Encapsulation-oriented vs. Timing-oriented Strategies for Necrotizing Pancreatitis
Role: collaborator
Simultaneous Bilateral Radiofrequency Thalamotomy for Medication-Refractory Essential Tremor
Role: lead
Developing Prediction Models for Allograft Failure After Liver Transplantation
Role: collaborator
Autologous Cord Blood Cell Therapy for Neonatal Encephalopathy
Role: collaborator
Cytokines Associated With Cord Blood Cell Therapy for Neonatal Encephalopathy
Role: collaborator
Conversion From Total Intravenous Anesthesia Technique to Desflurane Anesthesia for Long Duration Neurosurgery
Role: lead
Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases
Role: lead
Supplemental Thyroxine Treatment for Preterm Infants With Hypothyroxinemia
Role: lead
Bifidobacterium Supplementation for Very Low Birth Weight Infants
Role: lead
Early Administration of Bifidobacterium to Very Low Birth Weight Infants
Role: lead
All 12 trials loaded